Galderma Group AG (GALD.SW): analysis and signal as of September 4, 2026

Published on September 5, 2026 at 08:14 · Updated on September 5, 2026 at 08:14 · by Aurélien Ambert, QDNA

Exchange : SIX Swiss Exchange · Sector : Healthcare

In short

The overall signal is weak, with a vote of 3/3 and no score provided. The technical breakdown below the 50-session moving average at -8,6 %, combined with a six-month overnight reversal, weighs more heavily than the nemolizumab catalyst and the defensive healthcare dynamic.

Current signal: weak (vote 3/3) divergence
Deterministic score: +4.5 → signal expected by the scale : strong (September 10, 2026)
Layers: fundamentals : positive, price : negative, risks : positive

Triggered rules

Rule	Weight
favors (GARP) a stock whose PEG is below 1, growth not yet paid for	+1.5
favors robust fundamental health (high Piotroski F-Score)	+1.5
favors a "fast grower" profile, high and durable earnings growth (> 20 %), to be cross-checked against the PEG	+1.0
moderately favors a positive 12-1 month momentum (tailwind), BUT guardrail: costly rotation, long-term reversal, momentum crashes, a conviction signal, not a rotation trigger	+0.5

Thesis

The thesis relies on the defensive healthcare sector being in an expansion phase and on the monetization of nemolizumab, which establishes a positive fundamental bias. The technical layer contradicts this bias by breaking the 50-session moving average by 8,6 %, with a negative six-month overnight reversal of -0,6 %. This flow fragility dominates the qualitative picture in the short term. Stabilization above the 50-session moving average and the publication of the first-half 2026 results constitute the verification framework for the scenario.

Bull case

The main catalyst is Nemluvio, with FDA authorization for chronic urticaria granted in December 2024 and a US launch scheduled for the first quarter of 2025. The 2025 guidance indicates constant-currency growth of 16 to 19 % and core EBITDA of 1,09 to 1,12 billion US dollars. The weighted macro regime remains bullish at 0.58, which favors the defensive nature of healthcare. These elements support the stock if flows return.

Bear case

The breakdown of the 50-session moving average stands at -8,6 %, a level that signals a deterioration in flows. The two-year overnight-to-intraday ratio comes out at 5,5 times, a profile interpreted as fragile participation, and the six-month overnight reversal stands at -0,6 %. The post-listing valuation, expressed as an estimated PER 2025 of around 30 times, leaves a reduced margin of safety. The first-half 2026 publications and the extended pipeline do not yet have verification under real-world conditions.

Scenarios

The bullish scenario, with a probability of 30 %, sees Nemluvio outperform, indications expand and the price move back above the 50-session moving average, for a target of 175 to 185 CHF. The central scenario, with a probability of 45 %, expects consolidation between 150 and 165 CHF before the catalysts are validated. The bearish scenario, with a probability of 25 %, expects a break of 150 CHF, a negative effect from GLB-1 and a move back toward 130 to 140 CHF, with a maximum loss of -18 % from 158,65.

Risks

The main risks are the persistence of the technical breakdown, a high valuation after the listing and the absence of verified data on upcoming publications. The flow structure, with an overnight-to-intraday ratio of 5,5 times, exposes the stock to a continuation of the downward move. The real performance of Nemluvio and the development of the expanded pipeline, including GLB-1, will determine whether the correction extends or the positive bias resumes.

Signal history (last 12 months)

Date	Signal	New fact
September 4, 2026	weak (3/3)	No new fact has been verified. The deterministic signal remains unchanged and no figure subsequent to the provided layers can be confirmed during this session, since those layers may be outdated.

Frequently asked questions

Why is the signal weak despite positive fundamental arguments?

The overall signal incorporates the technical layer in addition to the fundamental arguments. The breakdown of the 50-session moving average at -8,6 % and the negative six-month overnight reversal signal a fragility in flows that carries more weight in the short term. The qualitative picture remains positive, but the technical verdict prevents adopting a stronger signal.

What does the overnight-to-intraday ratio of 5,5 times measure?

This ratio compares the magnitude of moves between the close and the open with the magnitude of variations during the session. A value of 5,5 times indicates a significant share of moves outside the session, often associated with retail investor flows rather than institutional orders. This structure makes the price holding more fragile and explains the weight given to the technical layer in the verdict.

What is the expected effect of Nemluvio in the thesis?

Nemluvio is the main bullish catalyst. Its FDA authorization for chronic urticaria dates back to December 2024, with a launch in the United States in the first quarter of 2025. The 2025 guidance provides for growth of 16 to 19 % in constant currencies and core EBITDA of 1,09 to 1,12 billion dollars. These figures support the thesis if the technical flows stabilize.

Why is the PER 2025 of approximately 30 times mentioned as a risk?

The estimated PER 2025 of around 30 times corresponds to a high valuation for a recently listed company. Such a valuation leaves little room for error in the event of an operational disappointment, for example if Nemluvio disappoints or GLB-1 is delayed. The market has already priced in part of the good news, which increases the price sensitivity to the first-half 2026 publications.

Which elements need to be verified in the upcoming publications?

The first-half 2026 results must be measured against expectations, as must the progress of the extended pipeline. The technical layer must move back above the 50-session moving average to reduce the fragility in flows highlighted by the overnight-to-intraday ratio. Without these confirmations, the bullish thesis remains fragile, but the central scenario still has the highest probability.

Sources

No official filing is attached to this stock in the database to date. The figures quoted above come from an automated arbitration: they have not been re-checked one by one.

Automated AI analysis: limitations and transparency

This content is an automated analysis produced using artificial intelligence. Personal analysis for information purposes — no personalised investment advice. MMR content consists of general research. It does not take account of your financial circumstances, objectives or risk tolerance. Data, analyses and results, including those produced using artificial intelligence, may contain errors, be incomplete or become outdated. No return or outcome is guaranteed. All investments carry a risk of partial or total loss of capital. Past performance and simulations do not predict future results. Before making any decision, check information against original sources and, where necessary, consult an authorised professional. You remain responsible for your investment decisions. This notice does not exclude or limit any liability that cannot legally be excluded or limited.
Tool and analysis: QDNA, Aurélien Ambert.
Analysis (arbitration) completed on September 4, 2026; this page was completed on September 5, 2026 at 08:14 (UTC).
Interests: no position in the stock analysed (GALD.SW) is recorded in the data consulted on September 12, 2026 (UTC). This does not confirm the absence of holdings or other interests. The situation at the analysis publication date has not been reconstructed.
This declaration covers only recorded positions in this stock; it is not an exhaustive verification of other interests or remuneration.
Methodology: analysis chain, score formula and scale described on the public methodology page.
Analysis horizon: 2035.